Literature DB >> 26451848

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.

Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, Cecilia L Moore, Marcello H Losso, Chidi A Nwizu, Lerato Mohapi, Stephen J Kerr, Annette H Sohn, Hedy Teppler, Boris Renjifo, Jean-Michel Molina, Sean Emery, David A Cooper.   

Abstract

Entities:  

Year:  2015        PMID： 26451848      PMCID： PMC4599832          DOI： 10.1371/journal.pone.0140623

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


× No keyword cloud information.
The group author, SECOND-LINE, was omitted from the author byline and should be listed as the fifteenth author. Please see the full list of contributing authors, as well as their full authorship contributions in the Acknowledgements section of the published article.
  1 in total

1.  Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.

Authors:  Janaki Amin; Mark A Boyd; Nagalingeswaran Kumarasamy; Cecilia L Moore; Marcello H Losso; Chidi A Nwizu; Lerato Mohapi; Stephen J Kerr; Annette H Sohn; Hedy Teppler; Boris Renjifo; Jean-Michel Molina; Sean Emery; David A Cooper
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240
  1 in total
  2 in total

1.  Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.

Authors:  Dami Collier; Collins Iwuji; Anne Derache; Tulio de Oliveira; Nonhlanhla Okesola; Alexandra Calmy; Francois Dabis; Deenan Pillay; Ravindra K Gupta
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

2.  Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.

Authors:  Obiageli Offor; Netanya Utay; David Reynoso; Anoma Somasunderam; Judith Currier; Jordan Lake
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.